Arotinoid acid (Ro 13-7410): a pilot study in dermatology.
Ro 13-7410 was given to 29 patients (a total of 38 treatment courses) for 7.5 weeks (range 4-23). This compound is one of the most potent retinoids ever synthetized and has the highest affinity to human skin cellular retinoic-acid-binding protein. At therapeutically active doses, it did not induce the commonly seen mucocutaneous signs of retinoid toxicity such as scaling and cheilitis; over 0.5 microgram/kg body weight/day, it very frequently induced an eczematous retinoid dermatitis. This pilot study provides some indications on what appears to be in several aspects a drug quite distinct from retinoids previously used in humans.
Saurat
J H
JH
Clinique de Dermatologie, Hôpital Cantonal Universitaire, Genève, Suisse.
Mérot
Y
Y
Borsky
M
M
Abba
Z
Z
Hirschel-Scholz
S
S
D000328:Adult; D000368:Aged; D001565:Benzoates / Q000009:adverse effects / Q000627:therapeutic use*; D003872:Dermatitis / Q000209:etiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011536:Prurigo / Q000188:drug therapy; D011565:Psoriasis / Q000188:drug therapy; D012176:Retinoids / Q000009:adverse effects / Q000627:therapeutic use*; D012871:Skin Diseases / Q000188:drug therapy*
D001565:Benzoates; D012176:Retinoids; C038864:4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid